Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

DexCom, Inc. (DXCM) Balance Sheet

As of 2026-06-30 (10-Q), DexCom, Inc. (DXCM) reported total assets of $6.5B, total liabilities of $3.8B and shareholders' equity of $2.6B, according to EquiReason's reading of its SEC filings. Cash and equivalents: $1.1B.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

DXCMDexCom, Inc.Follow DXCM — free
Medical Devices · Healthcare
—
Price chart with a free account
Market cap
29.4B
P/E TTM
30.9
Dividend yield
—
52-week
—
Next earnings
10 Feb, in 109 days
LineFY2011
Dec 11
FY2012
Dec 12
FY2013
Dec 13
FY2014
Dec 14
FY2015
Dec 15
FY2016
Dec 16
FY2017
Dec 17
FY2018
Dec 18
FY2019
Dec 19
FY2020
Dec 20
FY2021
Dec 21
FY2022
Dec 22
FY2023
Dec 23
FY2024
Dec 24
FY2025
Dec 25
Latest
Jun 26
Trend
Cash and equivalents0.000.010.040.070.090.090.441.140.450.821.050.640.570.610.921.11
Short-term investments0.080.040.010.010.030.030.110.09——1.361.812.161.73——
Receivables———0.040.070.100.130.230.290.430.510.710.971.011.221.26
Inventory0.010.010.010.020.040.050.050.070.120.230.360.310.560.540.630.73
Current assets0.100.080.090.150.230.280.741.701.973.423.683.674.434.304.034.09
Total assets0.120.110.120.180.290.400.901.922.404.294.935.396.266.486.346.46
Current liabilities0.010.020.030.040.070.100.140.220.360.610.721.841.562.932.142.36
Long-term debt—0.010.010.00————————————
Short-term debt——————————0.000.770.001.200.00—
Total liabilities0.020.030.040.040.070.120.481.251.512.462.893.264.204.383.593.83
Shareholders' equity0.100.080.080.140.220.280.420.660.881.832.042.132.072.102.752.62

USD billions · SEC XBRL

DexCom, Inc. — questions

How much cash does DexCom, Inc. have?
$1.1B in cash and cash equivalents as of 2026-06-30.
What are DexCom, Inc.'s total assets?
$6.5B as of 2026-06-30.
What is DexCom, Inc.'s shareholders' equity?
$2.6B as of 2026-06-30.

Every figure on this page comes from DexCom, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.